Program
BCL6 Molecular Glue LY4584180
Its studies are mostly in Lymphoma, Follicular, led by Eli Lilly.
Furthest: phase 1, since Nov 7, 20251 company-led study, 1 open or runningNext primary completion: Sep 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 11 open or running | phase 1since Nov 7, 2025 | Nov 7, 2025 | Sep 2028phase 1 · NCT07226843 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 7, 2025First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT07226843 · 460 planned · United States, France, Germany and more
- Oct 6, 2026Primary completion moved from 2027-04 to 2028-09Date moved laterphase 1 · +17 months · NCT07226843
Ahead
- Sep 2028Primary completion: phase 1 study in Lymphoma, Non-HodgkinNCT07226843
TargetBeta
BCL6 →read by rule
“An orally bioavailable molecular glue targeting B-cell lymphoma 6 protein (BCL6; BCL-6), ”NCIt, by rule
Other programs on BCL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| BCL6 Degrader TLN-121rule | treeline-biosciences-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07226843Lymphoma, Non-Hodgkin · United States, France, Germany and more | 1 | Recruiting | Sep 2028 | 460 |
How it is read
Names in the registry
- “LY4584180”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.